Melanotan I is a MC1R agonist. It is filed in this library under skin & aging, a navigation topic rather than a statement of where it acts. As a regulatory matter it is not approved by the FDA for any use.
Regulatory status
Melanotan I is not approved by the FDA for any use.
It is sold outside the approved-drug system, which means no regulator has reviewed its manufacturing, its purity or its effects.
The evidence
3 sources on Melanotan I published between 2006 and 2015, each resolved to its journal of record. Titles are listed so you can judge the evidence rather than take a summary on trust.
Nearby
Before any compound, the useful question is what your bloodwork already says. The OPTML Score reads a full panel against optimal ranges.
See the OPTML ScoreEducational reference only. This page explains what has been published about Melanotan I. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides